News stories about Peregrine Pharmaceuticals (NASDAQ:PPHM) have been trending somewhat positive recently, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Peregrine Pharmaceuticals earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 48.4329021806497 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Stock Futures Rise as Irma Weakens to Tropical Storm and North Korea Is Quiet (thestreet.com)
- Your Weekly Pharma Scoop: Valeant’s CRL Resolution, Eagle Undervalued, Array Positive Results (seekingalpha.com)
- Keep Close Watch On ALDX Today, ABBV Just Hit Another High, Fennec Uplisted (rttnews.com)
- PEREGRINE PHARMACEUTICALS INC : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) (4-traders.com)
- Investor Network: Peregrine Pharmaceuticals, Inc. to Host Earnings Call (finance.yahoo.com)
Shares of Peregrine Pharmaceuticals (NASDAQ:PPHM) traded down 0.63% during trading on Wednesday, hitting $3.13. The stock had a trading volume of 21,045 shares. The firm’s 50-day moving average is $3.58 and its 200-day moving average is $4.15. The firm’s market cap is $140.14 million. Peregrine Pharmaceuticals has a one year low of $1.97 and a one year high of $5.78.
Peregrine Pharmaceuticals (NASDAQ:PPHM) last released its quarterly earnings results on Monday, September 11th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.06. The company had revenue of $27.08 million for the quarter, compared to analysts’ expectations of $15.22 million. Peregrine Pharmaceuticals had a negative return on equity of 40.46% and a negative net margin of 23.15%. Equities research analysts forecast that Peregrine Pharmaceuticals will post ($0.40) EPS for the current year.
Several analysts have commented on PPHM shares. BidaskClub raised Peregrine Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, July 17th. ValuEngine raised Peregrine Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, June 20th. Noble Financial reissued a “buy” rating on shares of Peregrine Pharmaceuticals in a research note on Monday, July 31st. Finally, Zacks Investment Research downgraded Peregrine Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 21st. One analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $4.38.
WARNING: This piece of content was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/2888640/peregrine-pharmaceuticals-pphm-earns-daily-coverage-optimism-score-of-0-14.html.
Peregrine Pharmaceuticals Company Profile
Peregrine Pharmaceuticals, Inc (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts.
Receive News & Ratings for Peregrine Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peregrine Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.